Results 51 to 60 of about 310,703 (307)

Acute Left Ventricular Ballooning: Tools to Differentiate Hypertrophic Cardiomyopathy with Outflow Obstruction from Neurohumoral Takotsubo Syndrome

Reviews in Cardiovascular Medicine, 2023
Despite considerable interest in the syndrome of acute left ventricular (LV) ballooning, its pathophysiology has remained ill-defined. In this review, we explore observational data describing two etiologies of acute LV ballooning: neurohumoral classic ...
Arushi Singh, Louai Razzouk, Daniele Massera, Mark V. Sherrid   +3 more
doaj   +1 more source

The multi-modality cardiac imaging approach to the Athlete's heart: an expert consensus of the European Association of Cardiovascular Imaging [PDF]

, 2015
The term 'athlete's heart' refers to a clinical picture characterized by a slow heart rate and enlargement of the heart. A multi-modality imaging approach to the athlete's heart aims to differentiate physiological changes due to intensive training in the
Abergel, Abhayaratna, Andersson, Angell, Bartram, Basavarajaiah, Blair, Bossone, Bruder, Caso, Chandra, Corrado, Corrado, D'Andrea, D'Andrea, D'Andrea, D'Andrea, D'Andrea, D'Andrea, D'Andrea, Di Paolo, Douglas, Estorch, Fagard, Fagard, Florescu, Gabrielli, Galderisi, Galderisi, Garber, George, Gilbert, Goldhammer, Grothues, Hauser, Hildick-Smith, Kalliokoski, Kim, Knutsen, La Gerche, La Gerche, Ljungqvist, Mahrholdt, Makan, Maron, Maron, Maron, Maron, Maron, Matsumura, Matsuo, Montgomery, Moon, Moon, Morganroth, Mousavi, Nagueh, Nottin, O'Hanlon, Pattynama, Payne, Pelliccia, Pelliccia, Petersen, Pluim, Prakken, Rehr, Richand, Rickers, Rudski, Saghir, Scharf, Scharhag, Schwartz, Semelka, Sen-Chowdhry, Sen-Chowdhry, Severino, Sharma, Shave, Shave, Spirito, Steinvil, Teramoto, Terry, Thomas, Urhausen, Vinereanu, Whyte, Wolfe, Zeppilli, Zoncu   +91 more
core   +4 more sources

Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice

European Heart Journal
Graphical Abstract Graphical Abstract Established (in blue) and emerging/potential (in orange) applications of genetic testing in hypertrophic cardiomyopathy.
Luis R Lopes, Carolyn Y Ho, P. M. Elliott   +2 more
semanticscholar   +1 more source

Changes in left atrial deformation in hypertrophic cardiomyopathy: Evaluation by vector velocity imaging. [PDF]

, 2012
OBJECTIVES: Hypertrophic cardiomyopathy (HCM) represents a generalized myopathic process affecting both ventricular and atrial myocardium. We assessed the global and regional left atrial (LA) function and its relation to left ventricular (LV) mechanics ...
Badran, HM, Faheem, N, Hassan, H, Nazmy, A, Saadan, H, Soltan, G, Yacoub, MH   +6 more
core   +2 more sources

Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.
Ingy Mahana, Angelica T. Mejia, Miriam R. Elman, Daniel Kamna, Olives Nguyen, Hailey Volk, Hongya Chen, Ahmad Masri   +7 more
doaj   +1 more source

Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy

Journal of Nanobiotechnology, 2018
Background Theranostic perfluorocarbon nanoprobes have recently attracted attention due to their fascinating versatility in integrating diagnostics and therapeutics into a single system.
Xueli Zhao, Wen Luo, Jing Hu, Lei Zuo, Jing Wang, Rui Hu, Bo Wang, Lei Xu, Jing Li, Meng Wu, Pan Li, Liwen Liu   +11 more
doaj   +1 more source

Cardiac hypertrophy and heart failure: from the case to review of literature [PDF]

, 2016
In response to an increased workload due to physiological or pathological stimuli, the heart may undergo a process of growth with increased muscle mass called cardiac hypertrophy. It is a particular mechanism of long term compensation used by the heart
Massoni, Francesco, Onofri, Emanuela, Ricci, Lidia, Ricci, Serafino, Simeone, Claudio   +4 more
core   +1 more source

Extreme hypertrophic cardiomyopathy [PDF]

Heart, 2003
A 21 year old Jamaican woman with hypertrophic cardiomyopathy (HCM) was referred for sudden death risk assessment. The initial diagnosis of HCM was made at the age of 13 years and mild exertional dyspnoea has occurred since age 15 (New York Heart Association functional class II), but without syncope or chest pain. There is no …
B J, Maron, S A, Casey, A K, Almquist
openaire   +2 more sources

Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Disopyramide is used to treat heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM) with known medium‐term efficacy and safety, while long‐term outcomes are unknown. Methods and Results A total of 92 consecutive
Daniele Massera, Mark V. Sherrid, Elizabeth Adlestein, Nadia Bokhari, Isabel C. Alvarez, Woon Y. Wu, Maria C. Reuter, Martin S. Maron, Barry J. Maron, Ethan J. Rowin   +9 more
doaj   +1 more source

Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction

Circulation, 2020
Supplemental Digital Content is available in the text. Background: The term “end stage” has been used to describe hypertrophic cardiomyopathy (HCM) with left ventricular systolic dysfunction (LVSD), defined as occurring when left ventricular ejection ...
Peter Marstrand, Larry Han, S. Day, I. Olivotto, E. Ashley, M. Michels, A. Pereira, S. Wittekind, A. Helms, S. Saberi, D. Jacoby, J. Ware, S. Colan, C. Semsarian, J. Ingles, N. Lakdawala, Carolyn Y. Ho   +16 more
semanticscholar   +1 more source